Sitaxentan

	WikiDoc Resources for Sitaxentan
Articles
Most recent articles on Sitaxentan Most cited articles on Sitaxentan Review articles on Sitaxentan Articles on Sitaxentan in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sitaxentan Images of Sitaxentan Photos of Sitaxentan Podcasts & MP3s on Sitaxentan Videos on Sitaxentan
Evidence Based Medicine
Cochrane Collaboration on Sitaxentan Bandolier on Sitaxentan TRIP on Sitaxentan
Clinical Trials
Ongoing Trials on Sitaxentan at Clinical Trials.gov Trial results on Sitaxentan Clinical Trials on Sitaxentan at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sitaxentan NICE Guidance on Sitaxentan NHS PRODIGY Guidance FDA on Sitaxentan CDC on Sitaxentan
Books
Books on Sitaxentan
News
Sitaxentan in the news Be alerted to news on Sitaxentan News trends on Sitaxentan
Commentary
Blogs on Sitaxentan
Definitions
Definitions of Sitaxentan
Patient Resources / Community
Patient resources on Sitaxentan Discussion groups on Sitaxentan Patient Handouts on Sitaxentan Directions to Hospitals Treating Sitaxentan Risk calculators and risk factors for Sitaxentan
Healthcare Provider Resources
Symptoms of Sitaxentan Causes & Risk Factors for Sitaxentan Diagnostic studies for Sitaxentan Treatment of Sitaxentan
Continuing Medical Education (CME)
CME Programs on Sitaxentan
International
Sitaxentan en Espanol Sitaxentan en Francais
Business
Sitaxentan in the Marketplace Patents on Sitaxentan
Experimental / Informatics
List of terms related to Sitaxentan

Sitaxentan
Clinical data
Synonyms	Sitaxsentan; TBC-11251
AHFS/Drugs.com	International Drug Names
[[Regulation of therapeutic goods \|Template:Engvar data]]	EU EMA: by INN;
Routes of; administration	Oral
ATC code	C02KX03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ;
Pharmacokinetic data
Bioavailability	70 to 100%
Protein binding	>99%
Metabolism	Hepatic (CYP2C9- and CYP3A4-mediated)
Elimination half-life	10 hours
Excretion	Renal (50 to 60%); Fecal (40 to 50%)
Identifiers
	IUPAC name N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-2H-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide;
CAS Number	184036-34-8 ; 210421-64-0 (sodium salt);
PubChem CID	216235;
IUPHAR/BPS	3950;
DrugBank	DB06268;
ChemSpider	21106381;
UNII	J9QH779MEM;
KEGG	D07171;
ChEMBL	ChEMBL282724;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C18H15ClN2O6S2
Molar mass	454.906 g/mol
3D model (JSmol)	Interactive image;
	SMILES Cc1cc2OCOc2cc1CC(=O)c3sccc3S(=O)(=O)Nc4onc(C)c4Cl;

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH).^[1] It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity.^[2]

Mechanism of Action

Sitaxentan is a small molecule that blocks the action of endothelin (ET) on the endothelin-A (ET_A) receptor selectively (by a factor of 6000 compared to the ET_B).^[3] It is a sulfonamide class endothelin receptor antagonist (ERA) and is undergoing Food and Drug Administration (FDA) review for treating pulmonary hypertension. The rationale for benefit compared to bosentan, a nonselective ET blocker, is negligible inhibition of the beneficial effects of ET_B stimulation, such as nitric oxide production and clearance of ET from circulation. In clinical trials, the efficacy of sitaxentan has been much the same as bosentan, but the hepatotoxicity of sitaxentan outweighs its benefits. Dosing is once daily, as opposed to twice daily for bosentan.

Regulatory Status

On December 10, 2010 Pfizer announced it would be withdrawing sitaxentan worldwide (both from marketing and from all clinical study use), citing that it is a cause of fatal liver damage.^[2]

Sitaxentan was approved for marketing in the European Union in 2006, in Canada in 2006^[4] and in Australia in 2007. By February 2008 it had been launched commercially in Germany, Austria, The Netherlands, the United Kingdom, Ireland, France, Spain and Italy.

In March 2006, the FDA recommended an approvable status to sitaxentan but said it would not yet approve the product. In July 2006, sitaxentan received a second approvable letter stating that efficacy outcome issues raised in the context of the STRIDE-2 study were still unresolved. In July 2007, Encysive commenced a formal dispute resolution process in a preliminary meeting with the FDA. In September 2007 the company announced that it was making preparations for another phase III clinical trial (intended to be named STRIDE-5) to overcome the FDA's concerns.^[5] The takeover by Pfizer resulted in a reconfiguration and extension of these plans, to include combination therapy with sildenafil. The Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) was an ongoing program of three clinical trials conducted in the United States (ClinicalTtrials.gov identifiers: NCT00795639, NCT00796666 and NCT00796510) with anticipated completion dates between June 2010 and January 2014.

Adverse Effects

Adverse effects observed with sitaxentan are class effects of endothelin receptor antagonists, and include :

liver enzyme abnormalities (increased ALT and AST)
headache
edema
constipation
nasal congestion
upper respiratory tract infection
dizziness
insomnia
flushing

Because sitaxentan inhibits metabolism of warfarin, a decreased dose of warfarin is needed when co-administered with sitaxentan. This is because warfarin acts to prevent blood from clotting, and if it remains unmetabolized, it can continue to thin the blood.

References

↑ Barst RJ, Langleben D, Frost A; et al. (2004). "Sitaxsentan therapy for pulmonary arterial hypertension". American Journal of Respiratory Critical Care Medicine. 169 (4): 441–447. doi:10.1164/rccm.200307-957OC. PMID 14630619.
↑ ^2.0 ^2.1 Citing liver damage, Pfizer withdraws Thelin, Associated Press, December 12, 2010
↑ Girgis, RE; Frost, AE; Hill, NS; Horn, EM; Langleben, D; McLaughlin, VV; Oudiz, RJ; Robbins, IM; et al. (2007). "Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease". Annals of the rheumatic diseases. 66 (11): 1467–72. doi:10.1136/ard.2007.069609. PMC 2111639. PMID 17472992.
↑ "UPDATE 1-Encysive gets Canadian approval for hypertension drug". Reuters. 30 May 2007. Retrieved 2007-07-08.
↑ "Encysive Pharmaceuticals to Conduct Phase III Study With Thelin (Sitaxsentan Sodium) in Pulmonary Arterial Hypertension". PrimeNewswire via COMTEX News Network. 29 September 2007. Retrieved 2007-12-12.

External Links

http://www.drugs.com/nda/thelin_050714.html
Mucke HAM: Sitaxsentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity? Clinical Medicine: Therapeutics 2009:1 111–121.
ATS 2005. The International Conference of the American Thoracic Society. 20–25 May 2005. San Diego, CA.
Robyn J. Barst, MD; Stuart Rich, MD, FCCP; Allison Widlitz, MS, PA; Evelyn M. Horn, MD; Vallerie McLaughlin, MD and Joyce McFarlin, RN : Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial Hypertension Chest. 2002;121:1860-1868.
American Heart Association. Primary or Unexplained Pulmonary Hypertension

Template:PAH rx

[1] Barst RJ, Langleben D, Frost A; et al. (2004). "Sitaxsentan therapy for pulmonary arterial hypertension". American Journal of Respiratory Critical Care Medicine. 169 (4): 441–447. doi:10.1164/rccm.200307-957OC. PMID 14630619.

[Pfizer-2] 2.0 ^2.1 Citing liver damage, Pfizer withdraws Thelin, Associated Press, December 12, 2010

[3] Girgis, RE; Frost, AE; Hill, NS; Horn, EM; Langleben, D; McLaughlin, VV; Oudiz, RJ; Robbins, IM; et al. (2007). "Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease". Annals of the rheumatic diseases. 66 (11): 1467–72. doi:10.1136/ard.2007.069609. PMC 2111639. PMID 17472992.

[Thelin-4] "UPDATE 1-Encysive gets Canadian approval for hypertension drug". Reuters. 30 May 2007. Retrieved 2007-07-08.

[STRIDE-5-5] "Encysive Pharmaceuticals to Conduct Phase III Study With Thelin (Sitaxsentan Sodium) in Pulmonary Arterial Hypertension". PrimeNewswire via COMTEX News Network. 29 September 2007. Retrieved 2007-12-12.

[1]

[2]

[3]

[4]

[5]

v t e Antihypertensives (C02) and diuretics (C03)
Sympatholytic agents	Template:Navbox subgroup
Vasodilators	Diazoxide • hydrazinophthalazine (Hydralazine, Dihydralazine, Endralazine, Cadralazine) • Minoxidil • Nitroprusside • Phentolamine
Other antihypertensives	serotonin antagonist (Ketanserin) • endothelin receptor antagonist (Bosentan, Ambrisentan, Sitaxsentan) • MAOI (Pargyline) • THI (Metirosine)
Diuretics	Template:Navbox subgroup